EUVIMEDEUVIMED entdecken
Open Access

Protective efficacy of pirfenidone in rats with pulmonary fibrosis induced by bleomycin.

Baris Demirkol, Sule Gul, Mustafa Cörtük, Neslihan Akanıl Fener, Eminegül Yavuzsan, Ramazan Eren, Kursad Nuri Baydili, Mustafa Baki Çekmen, Erdogan Cetinkaya

Sarcoidosis vasculitis and diffuse lung diseases · 13.09.2023 · 40 (3) · e2023036-e2023036

DOI: 10.36141/svdld.v40i3.13847 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Sarcoidosis vasculitis and diffuse lung diseases, erschienen am 13.09.2023. Verfasst von Baris Demirkol und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Health Sciences Turkey, Basaksehir Cam and Sakura City Hospital. barisdemirkol34@gmail.com. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Bleomycin causes increased production of reactive oxygen species, leads to pulmonary toxicity, fibroblast activation, and fibrosis. OBJECTIVES: This study aimed to evaluate the protective effect of pirfenidone on bleomycin-induced lung toxicity in rats. METHODS: Twenty-eight adult rats were randomly divided into 3 groups; Bleomycin (B group, n=10), Bleomycin and Pirfenidone (B-PND group, n=13), and the control group (n=5). The bleomycin regimen was administered for 9 weeks. Pirfenidone was administered at 100 mg/kg daily. Total antioxidant level (TAS), total oxidant level (TOS), tumor necrosis factor (TNF-α), transforming growth factor (TGF-β1), matrix metalloproteinase-2 (MMP-2), plasminogen activator inhibitor (PAI) levels were studied. Histopathologically, sections were stained with Hematoxylin-eosin and Masson-trichrome for grading-scoring according to the Ashcroft score. RESULTS: Stage 3 fibrosis was observed in 50% of the B group rats, stage 3 and higher fibrosis was never detected in the B-PND group and the difference was statistically significant (p=0.003). When evaluating tissue inflammation, the inflammation was higher in the B-PND group than in the other groups (p

Schlagwörter

pirfenidonebleomycin-induced lung fibrosispulmonary fibrosisbleomycin pulmonary toxicitypleurisyoxidative stressantioxidant capacityTNF-αTGF-β1MMP-2

Autor:innen und Institutionen

  • University of Health Sciences Turkey, Basaksehir Cam and Sakura City Hospital. barisdemirkol34@gmail.com.
  • . suleeyhan@gmail.com.
  • . mcortuk@yahoo.com.
  • . neslihanakanilfener@gmail.com.
  • . yavuzsaneminegul@gmail.com.
  • . ramazaneren952@gmail.com.

Zitieren

APA

Demirkol, B., Gul, S., Cörtük, M., Akanıl Fener, N., Yavuzsan, E., Eren, R., Baydili, K. N., Çekmen, M. B., & Cetinkaya, E. (2023). Protective efficacy of pirfenidone in rats with pulmonary fibrosis induced by bleomycin. Sarcoidosis vasculitis and diffuse lung diseases, 40(3), e2023036-e2023036. https://doi.org/10.36141/svdld.v40i3.13847

Vancouver

Demirkol B, Gul S, Cörtük M, Akanıl Fener N, Yavuzsan E, Eren R, et al. Protective efficacy of pirfenidone in rats with pulmonary fibrosis induced by bleomycin. Sarcoidosis vasculitis and diffuse lung diseases. 2023;40(3):e2023036-e2023036. doi:10.36141/svdld.v40i3.13847

BibTeX
@article{Demirkol2023,
  author = {Demirkol, Baris and Gul, Sule and Cörtük, Mustafa and Akanıl Fener, Neslihan and Yavuzsan, Eminegül and Eren, Ramazan and Baydili, Kursad Nuri and Çekmen, Mustafa Baki and Cetinkaya, Erdogan},
  title = {Protective efficacy of pirfenidone in rats with pulmonary fibrosis induced by bleomycin},
  journal = {Sarcoidosis vasculitis and diffuse lung diseases},
  year = {2023},
  volume = {40},
  number = {3},
  pages = {e2023036--e2023036},
  doi = {10.36141/svdld.v40i3.13847}
}
Kostenlos starten →